ADDITIONAL INFORMATION CONTINUED EMPLOYEE REMUNERATION The number of employees, not being directors of the Company, who received remuneration and benefits in their capacity as employees totalling NZ $100,000 or more during the year, shown in bands denominated in Australian dollars, was as follows: Excluding share based payments 2025 $’000 2024 $’000 $90,000–$99,999 1 0 $100,000–$109,000 1 0 $120,000 – $129,999 – 1 $150,000 – $159,999 – 1 $170,000 – $179,000 1 – $180,000 – $189,999 1 1 $210,000 – $219,999 – 1 $230,000 – $239,999 1 – $250,000 – $259,999 – 1 $260,000 – $269,999 – 1 $270,000 – $279,999 1 – $280,000 – $289,999 1 – $290,000 – $299,999 – 1 $300,000 – $309,999 1 – $320,000 – $329,999 – 1 $330,000 – $339,999 1 1 $350,000 – $359,999 1 – Including share based payments 2025 $’000 2024 $’000 $110,000–$119,000 1 – $120,000 – $129,999 1 1 $180,000 – $189,999 – 1 $230,000 – $239,999 1 – $270,000 – $279,999 – 1 $280,000 – $289,999 – 1 $300,000 – $309,999 – 1 $320,000 – $329,999 1 – $340,000 – $349,999 1 1 $360,000 – $369,999 – 1 $480,000 – $489,999 – 1 $490,000 – $499,999 1 – $500,000 – $509,999 1 – $550,000 – $559,999 1 – $560,000 – $569,999 1 – $660,000 – $669,999 1 1 Neuren Pharmaceuticals Limited Annual Report 2025 61
RkJQdWJsaXNoZXIy MjE2NDg3